Chao Liu

Dr. Chao Liu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
NYNing Yan
Ning Yan
XSXiao-Long Shi
Xiao-Long Shi
LTLong-Qian Tang
Long-Qian Tang
DWDe-Feng Wang
De-Feng Wang
Xun LiXun Li
Xun Li
ZLZhao-Peng Liu
Zhao-Peng Liu
Glycogen synthase kinase 3β (GSK-3β) catalyses the hyperphosphorylation of tau protein in the Alzheimer’s disease (AD) pathology. A series of novel thieno[3,2-c]pyrazol-3-amine derivatives were designed and synthesised and evaluated as potential GSK-3β inhibitors by structure-guided drug rational design approach. The thieno[3,2-c]pyrazol-3-amine derivative 16b was identified as a potent GSK-3β inhibitor with an IC50 of 3.1 nM in vitro and showed accepted kinase selectivity. In cell levels, 16b showed no toxicity on the viability of SH-SY5Y cells at the concentration up to 50 μM and targeted GSK-3β with the increased phosphorylated GSK-3β at Ser9. Western blot analysis indicated that 16b decreased the phosphorylated tau at Ser396 in a dose-dependent way. Moreover, 16b effectively increased expressions of β-catenin as well as the GAP43, N-myc, and MAP-2, and promoted the differentiated neuronal neurite outgrowth. Therefore, the thieno[3,2-c]pyrazol-3-amine derivative 16b could serve as a promising GSK-3β inhibitor for the treatment of AD.

13 June 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
NYNing Yan
Ning Yan
FXFei Xie
Fei Xie
LTLong-Qian Tang
Long-Qian Tang
DWDe-Feng Wang
De-Feng Wang
XLXiang Li
Xiang Li
ZLZhao-Peng Liu
Zhao-Peng Liu

1 January 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SLSha-Sha Li
Sha-Sha Li
CZCheng-Mei Zhang
Cheng-Mei Zhang
JWJing-De Wu
Jing-De Wu
CLChao Liu
Chao Liu
ZLZhao-Peng Liu
Zhao-Peng Liu

6 July 2023 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MWMengmeng Wang
Mengmeng Wang
KQKunyu Qu
Kunyu Qu
PZPeipei Zhao
Peipei Zhao
XYXin Yin
Xin Yin
YMYiwei Meng
Yiwei Meng
XXia Xuekui
Xia Xuekui
Gemcitabine is an antimetabolite drug approved for the treatment of various cancers. However, its use is limited due to several issues such as stability, toxicity and drug resistance. Herein, we present the design and synthesis of a series of gemcitabine prodrugs with modifications on the 4-N-amino group by employing an acetylated L- or D-lysine moiety masked by different substitutions. Prodrugs 1–3 and 6–8 showed up to 2.4 times greater anticancer activity than gemcitabine in A549 lung cells, while they exhibited potent activity against BxPC-3 pancreatic cells with IC50 values in the range of 7–40 nM. Moreover, prodrugs 2–3 and 7–8 were found to be less potent against CTSL low expression Caco-2 cells and at least 69-fold less toxic towards human normal HEK-293T cells compared to gemcitabine, leading to improved selectivity and safety profiles. Further stability studies showed that representative prodrugs 2 and 7 exhibited enhanced metabolic stability in human plasma, human liver microsomes and cytidine deaminase. Prodrug 1 can be cleaved by tumor cell-enriched CTSL to release parent drug gemcitabine. Overall, these results demonstrated that acetylated lysine conjugated gemcitabine prodrugs could serve as promising leads for further evaluation as new anticancer drugs.

6 April 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
ZWZhao-Hui Wen
Zhao-Hui Wen
MWMeng-Meng Wang
Meng-Meng Wang
LLLing-Yun Li
Ling-Yun Li
PHPiet Herdewijn
Piet Herdewijn
RSRobert Snoeck
Robert Snoeck
CLChao Liu
Chao Liu

19 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KPKatherin Patsch
Katherin Patsch
CLChao Liu
Chao Liu
Grzegorz ZapotocznyGrzegorz Zapotoczny
Grzegorz Zapotoczny
YSYuanye Sun
Yuanye Sun
HSHarish Sura
Harish Sura
DRDaniel Ruderman
Daniel Ruderman
Small molecules that target the androgen receptor (AR) are the mainstay of therapy for lethal castration-resistant prostate cancer (CRPC), yet existing drugs lose their efficacy during continued treatment. This evolution of resistance is due to heterogenous mechanisms which include AR mutations causing the identical drug to activate instead of inhibit the receptor. Understanding in molecular detail the paradoxical phenomenon wherein an AR antagonist is transformed into an agonist by structural mutations in the target receptor is thus of paramount importance. Herein, we describe a reciprocal paradox: opposing antagonist and agonist AR regulation determined uniquely by enantiomeric forms of the same drug structure. The antiandrogen BMS-641988, which has ( R )-chirality at C-5 encompasses a previously uncharacterized ( S )-stereoisomer that is, surprisingly, a potent agonist of AR, as demonstrated by transcriptional assays supported by cell imaging studies. This duality was reproduced in a series of novel compounds derived from the BMS-641988 scaffold. Coupled with in silico modeling studies, the results inform an AR model that explains the switch from potent antagonist to high-affinity agonist in terms of C-5 substituent steric interactions with helix 12 of the ligand binding site. They imply strategies to overcome AR drug resistance and demonstrate that insufficient enantiopurity in this class of AR antagonist can confound efforts to correlate structure with function.